Antiproliferative Drugs for Restenosis Prevention.
Antiproliferative Drugs for Restenosis Prevention.
复制标题
DOI：
10.1016/j.iccl.2016.02.002
复制
发表时间：
2016-07-01
影响因子：
--
通讯作者：
Finn, Aloke Virmani
中科院分区：
文献类型：
--
作者：
Habib, Anwer;Finn, Aloke Virmani
心血管疾病是全世界死亡和残疾的主要原因。目前旨在治疗阻塞性血管疾病的症状和后果的治疗策略包括最佳药物治疗和基于导管的药物洗脱支架经皮冠状动脉介入治疗。药物洗脱支架含有抑制血管平滑肌细胞增殖的抗增殖药物，血管平滑肌细胞增殖是对损伤的反应，从而防止再狭窄。然而，目前批准用于药物洗脱支架的所有药物不能区分增殖的血管平滑肌细胞和内皮细胞，因此延迟了再内皮化和随后的血管愈合。
Cardiovascular disease is a leading cause of death and disability worldwide. Current treatment strategies aimed at treating the symptoms and consequences of obstructive vascular disease have embraced both optimal medical therapy and catheter-based percutaneous coronary intervention with drug-eluting stents. Drug-eluting stents elute antiproliferative drugs inhibiting vascular smooth muscle cell proliferation, which occurs in response to injury and thus prevents restenosis. However, all drugs currently approved for use in drug-eluting stents do not discriminate between proliferating vascular smooth muscle cells and endothelial cells, thus delaying re-endothelialization and subsequent vascular healing.